Publication Name	World Journal of Critical Care Medicine
Manuscript ID	73238
Country	United States

Received	2021-11-14 19:36
Peer-Review Started	2021-11-14 19:37
To Make the First Decision
Return for Revision	2022-04-07 02:42
Revised	2022-04-23 19:17
Second Decision	2022-06-15 02:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-06-18 21:06
Articles in Press	2022-06-18 21:06
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-06-28 07:06
Publish the Manuscript Online	2022-07-07 10:23

ISSN	2220-3141(online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Critical Care Medicine
Manuscript Type	Minireviews
Article Title	Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid
Manuscript Source	Unsolicited Manuscript
All Author List	Farrukh Ahmad
Funding Agency and Grant Number
Corresponding Author	Farrukh Ahmad, MD, Staff Physician, Department of Internal Medicine, Saint Vincent Hospital, 123, Summer Street, Worcester, MA 01608, United States. farrukh2.ahmad@stvincenthospital.com
Key Words	COVID-19; Acute respiratory distress syndrome; Medicinal nicotine; Cholinergic anti-inflammatory pathway; Corticosteroid
Core Tip	Cholinergic anti-inflammatory pathway is novel pathway of the inflammatory reflex. Activation of this pathway can suppress maladaptive inflammatory response seen in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). Nicotine is a potent activator of this pathway and may offer benefits in the management of COVID-19 ARDS, via immune suppressive effects similar to dexamethasone.
Publish Date	2022-07-07 10:23
Citation	Ahmad F. Medicinal nicotine in COVID-19 acute respiratory distress syndrome, the new corticosteroid. World J Crit Care Med 2022; 11(4): 228-235
URL	https://www.wjgnet.com/2220-3141/full/v11/i4/228.htm
DOI	https://dx.doi.org/10.5492/wjccm.v11.i4.228

Full Article (PDF)	WJCCM-11-228.pdf
Full Article (Word)	WJCCM-11-228.docx
Manuscript File	73238_Auto_Edited_LM.docx
Answering Reviewers	73238-Answering reviewers.pdf
Audio Core Tip	73238-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	73238-Conflict-of-interest statement.pdf
Copyright License Agreement	73238-Copyright license agreement.pdf
Peer-review Report	73238-Peer-review(s).pdf
Scientific Misconduct Check	73238-Bing-Gao CC-2.png
Scientific Editor Work List	73238-Scientific editor work list.pdf